Skip to content

US · CHRS · BIOTECHNOLOGY

Coherus Oncology, Inc. (CHRS) intrinsic value and stock valuation

$0.37as of 2026-11-21 · Mkt cap 177.49M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Coherus Oncology, Inc. DCF and intrinsic value

InvestorsCraft values CHRS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CHRS’s statements →

Coherus Oncology, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Redwood City, CA 94065 coherus.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$42.2M-38.4% 5y CAGRd
20122025
Net income
-$-170.29M
20122025
Free cash flow
-$-138.51M
20122025
Total equity
$61M-26.3% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$42.2M$267M$257.2M$211M$326.6M
Operating income-$-179.53M-$-111.67M-$-203.2M-$-256.88M-$-263.86M
Net income-$-170.29M$28.5M-$-237.89M-$-291.75M-$-287.1M
EPSd-$-1.41M$248.3K-$-2.53M-$-3.76M-$-3.81M
Operating cash flow-$-138.51M-$-20.44M-$-174.88M-$-241.12M-$-37.43M
Capital expenditure$0.00$0.00-$-290K-$-2.04M-$-1.29M
Free cash flow-$-138.51M-$-20.44M-$-175.17M-$-243.16M-$-38.72M
Total assets$258.3M$448.5M$629.6M$480.9M$679.3M
Total debt$40.3M$269.9M$480.8M$480.4M$419M
Net debt-$-48.54M$143.9M$378M$416.9M$1.83M
Total equity$61M-$-131.99M-$-193.43M-$-137.42M$97.7M
Cash and short-term investments$172.1M$126M$117.8M$191.7M$417.2M
Income statement
20252024202320222021
Revenue$42.2M$267M$257.2M$211M$326.6M
Cost of revenue$17.7M$117.6M$159M$70.1M$57.6M
Gross profit$24.4M$149.4M$98.3M$141M$269M
Research and development expenses$105M$93.3M$109.4M$199.4M$363.1M
Selling, general and administrative expenses$99M$150.4M$185.6M$198.5M$169.7M
Other expenses$0.00$17.3M$6.4M$0.00$0.00
Operating expenses$204M$261.1M$301.5M$397.8M$532.8M
Cost and expenses$221.7M$378.6M$460.4M$467.9M$590.4M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$9M$27.2M$40.5M$32.5M$23M
Depreciation and amortization$3.92M$5.28M$3.79M$3.7M$3.45M
Ebitda-$-170.2M$60.9M-$-193.94M-$-255.58M-$-260.69M
Operating income-$-179.53M-$-111.67M-$-203.2M-$-256.88M-$-263.86M
Total other income/expenses, net-$-3.59M$140.2M-$-35.07M-$-34.87M-$-23.24M
Income before tax-$-183.12M$28.5M-$-238.27M-$-291.75M-$-287.1M
Income tax expense$0.00$0.00-$-380K$0.00$0.00
Net income-$-170.29M$28.5M-$-237.89M-$-291.75M-$-287.1M
Weighted average shares outstanding$120.4M$114.6M$94.2M$77.6M$75.5M
Weighted average diluted shares outstanding$120.4M$114.8M$94.2M$77.6M$75.5M
Balance sheet
20252024202320222021
Cash and short-term investments$172.1M$126M$117.8M$191.7M$417.2M
Net receivables$18.4M$122.3M$260.5M$110M$123M
Inventory$3.17M$70.1M$62.6M$38.8M$37.6M
Total current assets$206.7M$341.6M$475.6M$381.2M$602.3M
Property, plant and equipment, net$1.34M$2.84M$5.12M$8.75M$7.81M
Goodwill and intangible assets$46.2M$53.7M$71.7M$5.93M$3.56M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$51.6M$107M$154M$99.6M$77M
Total assets$258.3M$448.5M$629.6M$480.9M$679.3M
Accounts payable$9.91M$28.5M$35.2M$11.5M$16.2M
Short-term debt$1.83M$1.69M$2.15M$4.32M$3.49M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$141.9M$283M$331.8M$138.7M$165.3M
Long-term debt$38.5M$268.2M$478.7M$476.1M$415.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$55.5M$297.5M$491.3M$479.6M$416.3M
Capital lease obligations$3.29M$4.98M$7.47M$9.36M$10.7M
Total liabilities$197.3M$580.5M$823M$618.3M$581.6M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-1.38B-$-1.55B-$-1.58B-$-1.34B-$-1.05B
Accumulated other comprehensive income (loss)-$-200K-$-280K-$-250K-$-250K-$-270K
Total equity$61M-$-131.99M-$-193.43M-$-137.42M$97.7M
Total investments$83.3M$0.00$14.9M$128.1M$0.00
Total debt$40.3M$269.9M$480.8M$480.4M$419M
Net debt-$-48.54M$143.9M$378M$416.9M$1.83M
Cash flow statement
20252024202320222021
Net income$168M$28.5M-$-237.89M-$-291.75M-$-287.1M
Depreciation and amortization$3.92M$5.28M$3.79M$3.7M$3.45M
Stock-based compensation$17M$27.8M$43.1M$50.7M$51.4M
Change in working capital-$-5.84M$55.9M-$-36.83M-$-79.26M$42.4M
Accounts receivable$93.6M$149.4M-$-150.68M$13.1M$34.1M
Inventory-$-17.11M-$-31.95M-$-46.73M-$-47.35M-$-6.25M
Accounts payable-$-19.56M-$-3.94M$23.8M-$-4.55M$870K
Net cash provided by operating activities-$-138.51M-$-20.44M-$-174.88M-$-241.12M-$-37.43M
Investments in property, plant and equipment$0.00$0.00-$-290K-$-2.04M-$-1.29M
Acquisitions, net$0.00$0.00$840K$0.00$1.29M
Net cash used for investing activities$375.1M$230.3M$144.6M-$-166.85M-$-138.41M
Common stock issued$8.25M$1.46M$74.2M$6.36M$40.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-273.7M-$-186.97M$69.6M$54.3M$51.9M
Net change in cash-$-37.13M$22.9M$39.3M-$-353.65M-$-123.96M
Cash at end of period$89.1M$126.3M$102.9M$64M$417.6M
Operating cash flow-$-138.51M-$-20.44M-$-174.88M-$-241.12M-$-37.43M
Capital expenditure$0.00$0.00-$-290K-$-2.04M-$-1.29M
Free cash flow-$-138.51M-$-20.44M-$-175.17M-$-243.16M-$-38.72M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Coherus Oncology, Inc.

        Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.

        CEO
        Dennis Lanfear
        Employees
        145
        Beta
        0.98

        Explore

        Frequently asked questions

        What is the intrinsic value of Coherus Oncology, Inc. (CHRS)?

        InvestorsCraft does not currently publish an intrinsic value for CHRS. How the IC value is calculated.

        Is CHRS undervalued?

        InvestorsCraft does not publish an undervaluation signal for CHRS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.